Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis

CNU IR > College of Smart Living > Dept. of Life and Health Science > Periodical Articles > Item 310902800/34697

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34697

Title:	Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis
Authors:	Chung, Mu-Chi Hsu, Hui-Tsung Chang, Chao-Hsiang Hung, Peir-Haur Hsiao, Po-Jen Wu, Laing-You Wu, Ming-Ju Shieh, Jeng-Jer Chung, Chi-Jung
Contributors:	Taichung Veterans General Hospital National Chung Hsing University National Chung Hsing University Asia University Taiwan China Medical University Taiwan China Medical University Taiwan China Medical University Hospital - Taiwan Chia-Yi Christian Hospital Department of Applied Life Science and Health, Chia Nan University of Pharmacy & Science National Chung Hsing University Taichung Veterans General Hospital China Medical University Taiwan China Medical University Hospital - Taiwan
Keywords:	cardiovascular outcomes empagliflozin metaanalysis mortality cancer
Date:	2022
Issue Date:	2023-12-11 14:05:42 (UTC+8)
Publisher:	NATURE PORTFOLIO
Abstract:	Sodium-glucose cotransporter 2 inhibitor (SGLT2i) potentially decrease all-cause and cardiovascular death, however, associations with non-cardiovascular death remain unclear. Therefore, we investigated SGLT2i associations with death and the cause of death. We used the Taiwanese National Health Institutes Research database linked to the National Register of Deaths (NRD). Incident type 2 diabetes mellitus (T2DM) patients and propensity score matched T2DM SGLT2i and Dipeptidyl peptidase 4 inhibitor (DPP4i) users were investigated. The index year was the SGLT2i or DPP4i prescription date from May 2016. Patients were followed-up until death or December 2018. Deaths verified by the NRD and grouped accordingly. Multiple Cox proportional hazards models were used. In total, 261,211 patients were included in the population; 47% of the patients were female and the average age was 62 years. The overall incidence of all-cause death was 8.67/1000 patient-years for SGLT2i and 12.41 for DPP4i users during follow-up. After adjusting for potential risk factors in the propensity score matched population, SGLT2i users were associated with lower risks of all-cause death, cardiovascular death, cancer death, and non-cancer, non-vascular death compared with DPP4i-users. For specific death causes, significantly lower death risks from heart disease, cerebrovascular disease, and accidents were associated with SGLT2i-use. SGLT2i benefits for T2DM patients were not different across subgroups. Compared with DPP4i-use, SGLT2i-use for T2DM was associated with lower disease and death risk.
Relation:	SCIENTIFIC REPORTS, v.12, n.10147
Appears in Collections:	[Dept. of Life and Health Science] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	234	View/Open
s41598-022-13760-7.pdf		1234Kb	Adobe PDF	136	View/Open

Loading...